184 related articles for article (PubMed ID: 37467016)
1. A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help.
Curran KJ; Nikiforow S; Bachier C; Hsu YM; Maloney D; Maus MV; McCarthy P; Porter D; Shi P; Shpall EJ; William B; Wacker K; Warkentin P; Heslop HE
Blood Adv; 2024 Feb; 8(4):1053-1061. PubMed ID: 37467016
[TBL] [Abstract][Full Text] [Related]
2. Developing and Monitoring a Standard-of-Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory Program.
Dulan SO; Viers KL; Wagner JR; Clark MC; Chang B; Gorospe GL; Londrc A; Brown AS; Rosenthal J; Smith EP; Forman SJ; Snyder DS; Budde LE
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1386-1393. PubMed ID: 32439475
[TBL] [Abstract][Full Text] [Related]
3. Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies.
Nikiforow S; Frigault MJ; Frey NV; Gardner RA; Komanduri KV; Perales MA; Kebriaei P; Warkentin PI; Pasquini M; Aho JL; Levine BL; Heslop HE; Hlucky TL; Habucky K; Gharibo M; Jagasia M; Locke FL
Transplant Cell Ther; 2023 Apr; 29(4):228-239. PubMed ID: 36709800
[TBL] [Abstract][Full Text] [Related]
4. The Why, what, and How of the New FACT standards for immune effector cells.
Maus MV; Nikiforow S
J Immunother Cancer; 2017; 5():36. PubMed ID: 28428885
[TBL] [Abstract][Full Text] [Related]
5. American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States.
Mahmoudjafari Z; Hawks KG; Hsieh AA; Plesca D; Gatwood KS; Culos KA
Biol Blood Marrow Transplant; 2019 Jan; 25(1):26-33. PubMed ID: 30266675
[TBL] [Abstract][Full Text] [Related]
6. American Society for Transplantation and Cellular Therapy Guidelines for Fellowship Training in Hematopoietic Cell Transplantation and Immune Effector Cell Therapy.
Jain T; Knight T; Alencar MC; Davis L; Rao K; Im A; Malone AK;
Transplant Cell Ther; 2022 Mar; 28(3):125-133. PubMed ID: 34954294
[TBL] [Abstract][Full Text] [Related]
7. National Survey of FACT-Accredited Cell Processing Facilities: Assessing Preparedness for Local Manufacturing of Immune Effector Cells.
Elsallab M; Bourgeois F; Maus MV
Transplant Cell Ther; 2024 Jun; 30(6):626.e1-626.e11. PubMed ID: 38494077
[TBL] [Abstract][Full Text] [Related]
8. Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy.
Kanate AS; Majhail NS; Savani BN; Bredeson C; Champlin RE; Crawford S; Giralt SA; LeMaistre CF; Marks DI; Omel JL; Orchard PJ; Palmer J; Saber W; Veys PA; Carpenter PA; Hamadani M
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1247-1256. PubMed ID: 32165328
[TBL] [Abstract][Full Text] [Related]
9. Validation of a flow cytometry-based method to quantify viable lymphocyte subtypes in fresh and cryopreserved hematopoietic cellular products.
Mfarrej B; Gaude J; Couquiaud J; Calmels B; Chabannon C; Lemarie C
Cytotherapy; 2021 Jan; 23(1):77-87. PubMed ID: 32718876
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective.
Goldsmith SR; Ghobadi A; Dipersio JF; Hill B; Shadman M; Jain T
Transplant Cell Ther; 2022 Nov; 28(11):727-736. PubMed ID: 35878743
[TBL] [Abstract][Full Text] [Related]
11. Considerations for immune effector cell therapy collections: a white paper from the American Society for Apheresis.
Liu HD; Su L; Winters JL; Thibodeaux SR; Park YA; Wu Y; Schwartz J; Zubair AC; Schneiderman J; Gupta GK; Ramakrishnan S; Aqui NA
Cytotherapy; 2022 Sep; 24(9):916-922. PubMed ID: 35398001
[TBL] [Abstract][Full Text] [Related]
12. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
[TBL] [Abstract][Full Text] [Related]
13. Cytokine Release Syndrome and Associated Acute Toxicities in Pediatric Patients Undergoing Immune Effector Cell Therapy or Hematopoietic Cell Transplantation.
Baumeister SHC; Mohan GS; Elhaddad A; Lehmann L
Front Oncol; 2022; 12():841117. PubMed ID: 35402259
[TBL] [Abstract][Full Text] [Related]
14. Voluntary accreditation of cellular therapies: Foundation for the Accreditation of Cellular Therapy (FACT).
Warkentin PI;
Cytotherapy; 2003; 5(4):299-305. PubMed ID: 12944235
[TBL] [Abstract][Full Text] [Related]
15. Cell Therapy Informatics: Updates on the Integration of HCT/IEC Functionalities into an Electronic Medical Record System in the US to Promote Efficiency, Patient Safety, Research, and Data Interoperability.
Ho VT; Klumpp TR; Liang WH; Prestegaard M; Horwitz M; Hamilton BK; Page K; Jaglowski S; Huber J; Martinez C; Shenoy V; Chen A; Rizzo D
Transplant Cell Ther; 2023 Sep; 29(9):539-547. PubMed ID: 37379969
[TBL] [Abstract][Full Text] [Related]
16. Payment and Care for Hematopoietic Cell Transplantation Patients: Toward a Specialized Medical Home for Complex Care Patients.
Gajewski JL; McClellan MB; Majhail NS; Hari PN; Bredeson CN; Maziarz RT; LeMaistre CF; Lill MC; Farnia SH; Komanduri KV; Boo MJ
Biol Blood Marrow Transplant; 2018 Jan; 24(1):4-12. PubMed ID: 28963077
[TBL] [Abstract][Full Text] [Related]
17. [Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Yakoub-Agha I; Ferrand C; Chalandon Y; Ballot C; Castilla Llorente C; Deschamps M; Gauthier J; Labalette M; Larghero J; Maheux C; Moreau AS; Varlet P; Pétillon MO; Pinturaud M; Rubio MT; Chabannon C
Bull Cancer; 2017 Dec; 104(12S):S43-S58. PubMed ID: 29174320
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?
Greenbaum U; Yalniz FF; Srour SA; Rezvani K; Singh H; Olson A; Blumenschein G; Hong DS; Shpall EJ; Kebriaei P
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1759-1769. PubMed ID: 32623078
[TBL] [Abstract][Full Text] [Related]
19. ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies.
Gardner RA; White C; Elsallab M; Farnia S; Fraint E; Grilley B; Bateman-House A; Grupp SA; Kenderian S; Locke FL; Nikiforow S; Oluwole OO; Rouce RH; Spiegel J; Shah NN; Sharma A; Komanduri K; Gill S
Transplant Cell Ther; 2024 May; ():. PubMed ID: 38762057
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
